{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:03:08Z","timestamp":1791576188703,"version":"4.3.4"},"reference-count":190,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["869105"],"award-info":[{"award-number":["869105"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["849569"],"award-info":[{"award-number":["849569"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 H150693"],"award-info":[{"award-number":["R01 H150693"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.xcrm.2025.102261","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T14:39:36Z","timestamp":1754059176000},"page":"102261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cardiometabolic disease and cardio-oncology: Insights from iPSC models and tissue engineering"],"prefix":"10.1016","volume":"6","author":[{"given":"Ana","family":"Kojic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102261_bib1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1126\/science.1241908","article-title":"27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology","volume":"342","author":"Nelson","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102261_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13813450801954303","article-title":"Obesity and cancer: pathophysiological and biological mechanisms","volume":"114","author":"Renehan","year":"2008","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.xcrm.2025.102261_bib3","doi-asserted-by":"crossref","first-page":"e1000201","DOI":"10.1371\/journal.pmed.1000201","article-title":"Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts","volume":"6","author":"Stocks","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib4","first-page":"900","article-title":"Shared Risk Factors for Cardiovascular Disease and Cancer: Implications for Preventive Health and Clinical Care in Oncology Patients","volume":"32","author":"Johnson","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/djk064","article-title":"Long-term risk of cardiovascular disease in 10-year survivors of breast cancer","volume":"99","author":"Hooning","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.xcrm.2025.102261_bib6","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ijc.34058","article-title":"Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer","volume":"151","author":"Forster","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102261_bib7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaccao.2024.09.012","article-title":"Cardiovascular Risk in Prostate Cancer: JACC: CardioOncology State-of-the-Art Review","volume":"6","author":"Leong","year":"2024","journal-title":"JACC. CardioOncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.629666","article-title":"Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis","volume":"11","author":"Dong","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCULATIONAHA.120.048655","article-title":"Crosstalk Between the Heart and Cancer: Beyond Drug Toxicity","volume":"142","author":"Moslehi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.xcrm.2025.102261_bib10","article-title":"The Promising Frontier of Cardiometabolic Syndrome: A New Paradigm in Cardiology","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.xcrm.2025.102261_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41569-023-00847-5","article-title":"Obesity and the risk of cardiometabolic diseases","volume":"20","author":"Valenzuela","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacc.2019.11.044","article-title":"Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review","volume":"75","author":"Mechanick","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/a-1263-0898","article-title":"Metabolic Syndrome Pathophysiology and Predisposing Factors","volume":"42","author":"Bovolini","year":"2021","journal-title":"Int. J. Sports Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1475-2891-7-10","article-title":"The underlying mechanisms for development of hypertension in the metabolic syndrome","volume":"7","author":"Yanai","year":"2008","journal-title":"Nutr. J."},{"key":"10.1016\/j.xcrm.2025.102261_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3502","article-title":"Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors","volume":"38","author":"Silveira Rossi","year":"2022","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"10.1016\/j.xcrm.2025.102261_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/aje\/155.6.487","article-title":"Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review","volume":"155","author":"Eichner","year":"2002","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib17","first-page":"13251","article-title":"Relationships between genetic polymorphisms of E670G in PCSK9 gene and coronary artery disease: a meta-analysis","volume":"8","author":"Adi","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1590\/1678-4685-gmb-2015-0267","article-title":"Polymorphisms FTO rs9939609, PPARG rs1801282 and ADIPOQ rs4632532 and rs182052 but not lifestyle are associated with obesity related-traits in Mexican children","volume":"39","author":"Mu\u00f1oz-Y\u00e1\u00f1ez","year":"2016","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.xcrm.2025.102261_bib19","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCRESAHA.123.322135","article-title":"Epigenetics of Early Cardiometabolic Disease: Mechanisms and Precision Medicine","volume":"132","author":"Baccarelli","year":"2023","journal-title":"Circ. Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41569-024-01017-x","article-title":"Cardiovascular disease and cancer: shared risk factors and mechanisms","volume":"21","author":"Wilcox","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s11886-023-01906-6","article-title":"Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism","volume":"25","author":"Zhao","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.xcrm.2025.102261_bib22","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2016.67.4283","article-title":"Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation","volume":"34","author":"Iyengar","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jacc.2021.12.017","article-title":"Inflammation, Aging, and Cardiovascular Disease: JACC Review Topic of the Week","volume":"79","author":"Liberale","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib24","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1093\/eurheartj\/ehz928","article-title":"Cardio-oncology: low-grade inflammation as a common pathway of cancer and cardiovascular disease","volume":"40","author":"Luscher","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.xcrm.2025.102261_bib25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.atherosclerosis.2018.12.006","article-title":"DNA methylation processes in atheosclerotic plaque","volume":"281","author":"Aavik","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.xcrm.2025.102261_bib26","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102261_bib27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1beta\/NLRP3 Inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib28","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.immuni.2022.06.022","article-title":"DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages","volume":"55","author":"Cobo","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102261_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111247","article-title":"SOX transcription factors direct TCF-independent WNT\/beta-catenin responsive transcription to govern cell fate in human pluripotent stem cells","volume":"40","author":"Mukherjee","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102261_bib30","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41419-018-0782-8","article-title":"SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt\/beta-catenin signaling pathway via trans-suppressing beta-catenin in cervical cancer","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2025.102261_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-018-0566-x","article-title":"Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease","volume":"10","author":"Zhu","year":"2018","journal-title":"Genome Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib32","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature08054","article-title":"Polar gradients of the DYRK-family kinase Pom1 couple cell length with the cell cycle","volume":"459","author":"Martin","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102261_bib33","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1182\/blood.2021011247","article-title":"DYRK1a mediates BAFF-induced noncanonical NF-kappaB activation to promote autoimmunity and B-cell leukemogenesis","volume":"138","author":"Li","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102261_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104139","article-title":"Inhibition of DYRK1A, via histone modification, promotes cardiomyocyte cell cycle activation and cardiac repair after myocardial infarction","volume":"82","author":"Lan","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2025.102261_bib35","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/febs.14347","article-title":"A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy","volume":"285","author":"Becker","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.xcrm.2025.102261_bib36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1161\/CIRCULATIONAHA.121.055727","article-title":"DYRK1B-STAT3 Drives Cardiac Hypertrophy and Heart Failure by Impairing Mitochondrial Bioenergetics","volume":"145","author":"Zhuang","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.xcrm.2025.102261_bib37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102261_bib38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ygyno.2021.06.022","article-title":"Risk of cardiovascular disease among women carrying BRCA mutations after risk-reducing bilateral salpingo-oophorectomy: A population-based study","volume":"162","author":"do Valle","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10549-016-4101-8","article-title":"The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy","volume":"162","author":"Pearson","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2025.102261_bib40","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacbts.2021.05.008","article-title":"Cardio-Oncology: Understanding the Intersections Between Cardiac Metabolism and Cancer Biology","volume":"6","author":"Karlstaedt","year":"2021","journal-title":"JACC. Basic Transl. Sci."},{"key":"10.1016\/j.xcrm.2025.102261_bib41","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/j.2040-4603.2016.tb00728.x","article-title":"Cardiac Metabolism in Perspective","volume":"6","author":"Taegtmeyer","year":"2016","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib42","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1161\/RES.0000000000000097","article-title":"Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association","volume":"118","author":"Taegtmeyer","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib43","first-page":"251","article-title":"Proposed regulation of gene expression by glucose in rodent heart","volume":"1","author":"Young","year":"2007","journal-title":"Gene Regul. Syst. Bio."},{"key":"10.1016\/j.xcrm.2025.102261_bib44","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1126\/science.abc8861","article-title":"Comprehensive quantification of fuel use by the failing and nonfailing human heart","volume":"370","author":"Murashige","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102261_bib45","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.15252\/emmm.201404669","article-title":"Cardiac LXRalpha protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization","volume":"7","author":"Cannon","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib46","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.tem.2021.07.006","article-title":"Ketone bodies for the failing heart: fuels that can fix the engine?","volume":"32","author":"Yurista","year":"2021","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2025.102261_bib47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tem.2013.09.002","article-title":"Ketone bodies as signaling metabolites","volume":"25","author":"Newman","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2025.102261_bib48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCRESAHA.110.224675","article-title":"O-GlcNAc signaling in the cardiovascular system","volume":"107","author":"Ngoh","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib49","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","article-title":"Cancer metabolism: looking forward","volume":"21","author":"Mart\u00ednez-Reyes","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102261_bib50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cmet.2019.08.013","article-title":"Mechanisms and Implications of Metabolic Heterogeneity in Cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2025.102261_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13041","article-title":"Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival","volume":"7","author":"Gaude","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102261_bib52","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.cell.2015.12.034","article-title":"Metabolic Heterogeneity in Human Lung Tumors","volume":"164","author":"Hensley","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102261_bib53","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41588-020-00753-3","article-title":"The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer","volume":"53","author":"Najumudeen","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102261_bib54","doi-asserted-by":"crossref","first-page":"21797","DOI":"10.1074\/jbc.C000023200","article-title":"Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc","volume":"275","author":"Osthus","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102261_bib55","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/modpathol.2008.111","article-title":"Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis","volume":"21","author":"Gurel","year":"2008","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.xcrm.2025.102261_bib56","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molcel.2005.03.027","article-title":"AMP-activated protein kinase induces a p53-dependent metabolic checkpoint","volume":"18","author":"Jones","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2025.102261_bib57","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/0008-5472.CAN-13-2034","article-title":"Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis","volume":"74","author":"Doherty","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib58","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg's contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102261_bib59","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102261_bib60","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41569-022-00698-6","article-title":"Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer","volume":"19","author":"Karlstaedt","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib61","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s41375-020-01043-x","article-title":"IDH1\/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis","volume":"35","author":"Kattih","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2025.102261_bib62","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib63","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib64","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1231677","article-title":"(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible","volume":"339","author":"Losman","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102261_bib65","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cmet.2015.06.009","article-title":"2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling","volume":"22","author":"Fu","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2025.102261_bib66","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib67","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1172\/JCI90644","article-title":"Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas","volume":"127","author":"Kohanbash","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102261_bib68","doi-asserted-by":"crossref","first-page":"16849","DOI":"10.1073\/pnas.0404840101","article-title":"A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria","volume":"101","author":"Rzem","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102261_bib69","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10545-012-9462-5","article-title":"Progress in understanding 2-hydroxyglutaric acidurias","volume":"35","author":"Kranendijk","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.xcrm.2025.102261_bib70","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1101\/gad.231233.113","article-title":"D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice","volume":"28","author":"Akbay","year":"2014","journal-title":"Genes Dev."},{"key":"10.1016\/j.xcrm.2025.102261_bib71","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1128\/MCB.01580-07","article-title":"Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein","volume":"28","author":"Lei","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2025.102261_bib72","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00005792-199711000-00001","article-title":"von Hippel-Lindau disease","volume":"76","author":"Maher","year":"1997","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.xcrm.2025.102261_bib73","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.devcel.2016.11.012","article-title":"Myocardial VHL-HIF Signaling Controls an Embryonic Metabolic Switch Essential for Cardiac Maturation","volume":"39","author":"Menendez-Montes","year":"2016","journal-title":"Dev. Cell"},{"key":"10.1016\/j.xcrm.2025.102261_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030290","article-title":"Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology","volume":"3","author":"Smith","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-0-387-73693-8_9","article-title":"Mutation of the von Hippel-Lindau gene alters human cardiopulmonary physiology","volume":"605","author":"Smith","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.xcrm.2025.102261_bib76","doi-asserted-by":"crossref","first-page":"H759","DOI":"10.1152\/ajpheart.00912.2015","article-title":"The von Hippel-Lindau Chuvash mutation in mice alters cardiac substrate and high-energy phosphate metabolism","volume":"311","author":"Slingo","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib77","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1056\/NEJMoa1907362","article-title":"Effects of Germline VHL Deficiency on Growth, Metabolism, and Mitochondria","volume":"382","author":"Perrotta","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib78","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature19795","article-title":"On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models","volume":"539","author":"Cho","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102261_bib79","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib80","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/gim.2017.261","article-title":"Genotype and phenotype correlation in von Hippel-Lindau disease based on alteration of the HIF-alpha binding site in VHL protein","volume":"20","author":"Liu","year":"2018","journal-title":"Genet. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib81","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1158\/0008-5472.CAN-20-2936","article-title":"Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate","volume":"81","author":"Goncalves","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib82","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.287.5454.848","article-title":"Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma","volume":"287","author":"Baysal","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102261_bib83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/321282","article-title":"Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma","volume":"69","author":"Astuti","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.xcrm.2025.102261_bib84","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/hmg\/ddq206","article-title":"SDHA is a tumor suppressor gene causing paraganglioma","volume":"19","author":"Burnichon","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2025.102261_bib85","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102261_bib86","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10689-019-00155-3","article-title":"Renal cell carcinoma in young FH mutation carriers: case series and review of the literature","volume":"19","author":"Hol","year":"2020","journal-title":"Fam. Cancer"},{"key":"10.1016\/j.xcrm.2025.102261_bib87","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/ng1095-144","article-title":"Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency","volume":"11","author":"Bourgeron","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102261_bib88","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouz\u00e9","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102261_bib89","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00431-006-0310-1","article-title":"Succinate dehydrogenase deficiency associated with dilated cardiomyopathy and ventricular noncompaction","volume":"166","author":"Davili","year":"2007","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.xcrm.2025.102261_bib90","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12933-021-01333-3","article-title":"Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","volume":"20","author":"Osuna-Prieto","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.xcrm.2025.102261_bib91","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.2337\/dcS13-2001","article-title":"Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer","volume":"36","author":"Gallagher","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xcrm.2025.102261_bib92","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaccao.2022.01.095","article-title":"Association of Cardiometabolic Disease With Cancer in the Community","volume":"4","author":"Liu","year":"2022","journal-title":"JACC. CardioOncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib93","first-page":"291","article-title":"Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study","volume":"22","author":"Borena","year":"2011","journal-title":"Cancer Causes Control."},{"key":"10.1016\/j.xcrm.2025.102261_bib94","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/HYPERTENSIONAHA.111.189258","article-title":"Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project","volume":"59","author":"Stocks","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.xcrm.2025.102261_bib95","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.2002.20.1.42","article-title":"Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study","volume":"20","author":"Goodwin","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib96","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ijc.22697","article-title":"Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition","volume":"121","author":"Jenab","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102261_bib97","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr3089","article-title":"Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes","volume":"14","author":"Ferguson","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib98","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/0008-5472.CAN-09-2141","article-title":"Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes","volume":"70","author":"Novosyadlyy","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib99","first-page":"1030","article-title":"Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis","volume":"62","author":"Wu","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib100","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","article-title":"Cancer cell metabolism: Warburg and beyond","volume":"134","author":"Hsu","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102261_bib101","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-05-4102","article-title":"Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation","volume":"66","author":"Nunez","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib102","first-page":"226","article-title":"Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction","volume":"32","author":"Heuson","year":"1972","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib103","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2337\/dc06-0922","article-title":"Prospective study of hyperglycemia and cancer risk","volume":"30","author":"Stattin","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xcrm.2025.102261_bib104","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00125-010-1933-3","article-title":"Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials","volume":"54","author":"Johnson","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.xcrm.2025.102261_bib105","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","article-title":"The role of lipids in cancer progression and metastasis","volume":"34","author":"Martin-Perez","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2025.102261_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030062","article-title":"Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors","volume":"7","author":"Mostaghel","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102261_bib107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016631","article-title":"The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor alpha-mediated signaling in cancer cells and in cardiomyocytes","volume":"6","author":"Lappano","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102261_bib108","article-title":"Obesity: A Chronic Low-Grade Inflammation and Its Markers","volume":"14","author":"Khanna","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.xcrm.2025.102261_bib109","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","article-title":"Interleukin-6 signaling pathway in targeted therapy for cancer","volume":"38","author":"Guo","year":"2012","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xcrm.2025.102261_bib110","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1038\/onc.2009.180","article-title":"Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells","volume":"28","author":"Sullivan","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102261_bib111","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.bbrc.2011.05.019","article-title":"TNFalpha enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl- and sulfotransferase genes involved in the synthesis of selectin ligands","volume":"409","author":"Radhakrishnan","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.xcrm.2025.102261_bib112","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/1940-6207.CAPR-10-0381","article-title":"Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland","volume":"4","author":"Subbaramaiah","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib113","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jaccao.2024.07.017","article-title":"Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations","volume":"6","author":"Raisi-Estabragh","year":"2024","journal-title":"JACC. CardioOncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib114","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaccao.2023.11.008","article-title":"Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes","volume":"6","author":"Fonoudi","year":"2024","journal-title":"JACC. CardioOncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib115","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC. CardioOncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib116","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC. CardioOncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib118","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMc1108849","article-title":"Reversible cardiomyopathy associated with sunitinib and sorafenib","volume":"365","author":"Uraizee","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib119","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMp1313140","article-title":"Cancer-drug discovery and cardiovascular surveillance","volume":"369","author":"Groarke","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2015.3709","article-title":"Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer","volume":"2","author":"Dang","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib121","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/CIRCRESAHA.121.318259","article-title":"Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors","volume":"128","author":"Fleming","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib122","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular Toxicities Associated With Ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib123","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular Toxic Effects of Targeted Cancer Therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib124","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2025.102261_bib141","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3389\/fphar.2020.00891","article-title":"A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors","volume":"11","author":"Jin","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102261_bib125","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41568-024-00715-5","article-title":"Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart","volume":"24","author":"Munir","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102261_bib126","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib127","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102261_bib128","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102261_bib129","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.xcrm.2025.102261_bib130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib131","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S1470-2045(20)30107-8","article-title":"Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research","volume":"21","author":"Johnson","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib132","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jaccao.2023.09.004","article-title":"Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis: Contemporary 1-Year Outcomes","volume":"5","author":"Itzhaki Ben Zadok","year":"2023","journal-title":"JACC. CardioOncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib143","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102261_bib133","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.jacc.2020.02.070","article-title":"Cardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T): A VigiBase Perspective","volume":"75","author":"Salem","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib134","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib135","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaccao.2023.07.009","article-title":"Incidence of MACE in Patients Treated With CAR-T Cell Therapy: A Prospective Study","volume":"5","author":"Lefebvre","year":"2023","journal-title":"JACC. CardioOncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib136","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2991\/chi.k.210718.001","article-title":"High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy","volume":"3","author":"Hu","year":"2021","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.xcrm.2025.102261_bib137","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/ajh.26259","article-title":"Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study","volume":"96","author":"Dolladille","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.xcrm.2025.102261_bib138","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaccao.2022.09.007","article-title":"Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer","volume":"5","author":"Waliany","year":"2023","journal-title":"JACC. CardioOncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib139","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-18-3749","article-title":"FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib142","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib144","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib145","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacbts.2016.05.008","article-title":"21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine","volume":"1","author":"Sheng","year":"2016","journal-title":"JACC. Basic Transl. Sci."},{"key":"10.1016\/j.xcrm.2025.102261_bib146","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11936-018-0627-x","article-title":"Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment","volume":"20","author":"Spetz","year":"2018","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib147","first-page":"3730","article-title":"The CO\/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy","volume":"117","author":"Suliman","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102261_bib148","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1161\/CIRCULATIONAHA.115.010484","article-title":"Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery","volume":"132","author":"Bellinger","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.xcrm.2025.102261_bib149","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","article-title":"Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives","volume":"23","author":"Bair","year":"2013","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib150","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/j.diabres.2011.04.011","article-title":"Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: a case report","volume":"93","author":"Lee","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.xcrm.2025.102261_bib151","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102261_bib152","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102261_bib153","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib154","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/FJC.0000000000001149","article-title":"Cardiometabolic Consequences of Targeted Anticancer Therapies","volume":"80","author":"Guha","year":"2022","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102261_bib155","series-title":"Idf diabetes atlas","article-title":"IDF Diabetes Atlas","author":"Magliano","year":"2021"},{"key":"10.1016\/j.xcrm.2025.102261_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109895","article-title":"The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity","volume":"117","author":"Zhang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.xcrm.2025.102261_bib157","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-024-01809-0","article-title":"Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications","volume":"9","author":"Cerneckis","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2025.102261_bib159","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1161\/ATVBAHA.120.314695","article-title":"Clinical Trial in a Dish: Using Patient-Derived Induced Pluripotent Stem Cells to Identify Risks of Drug-Induced Cardiotoxicity","volume":"41","author":"Lam","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.xcrm.2025.102261_bib158","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.biotechadv.2016.12.002","article-title":"Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening","volume":"35","author":"Smith","year":"2017","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.xcrm.2025.102261_bib160","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib161","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.stem.2021.08.006","article-title":"RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy","volume":"28","author":"Magdy","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2025.102261_bib162","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.121.055801","article-title":"Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity","volume":"145","author":"Magdy","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.xcrm.2025.102261_bib163","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2584","article-title":"High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells","volume":"9","author":"Sharma","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib164","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175447","article-title":"Modulation of NOX2 causes obesity-mediated atrial fibrillation","volume":"134","author":"Sridhar","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102261_bib165","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCULATIONAHA.123.065603","article-title":"USP28 Serves as a Key Suppressor of Mitochondrial Morphofunctional Defects and Cardiac Dysfunction in the Diabetic Heart","volume":"149","author":"Xie","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.xcrm.2025.102261_bib166","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1038\/s41467-023-39311-w","article-title":"Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages","volume":"14","author":"Groeger","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102261_bib167","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.stem.2018.03.009","article-title":"Super-Obese Patient-Derived iPSC Hypothalamic Neurons Exhibit Obesogenic Signatures and Hormone Responses","volume":"22","author":"Rajamani","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2025.102261_bib168","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41588-024-01694-x","article-title":"Protein-truncating variants in BSN are associated with severe adult-onset obesity, type 2 diabetes and fatty liver disease","volume":"56","author":"Zhao","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102261_bib169","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/stcltm\/szac030","article-title":"Toward Precision Medicine with Human Pluripotent Stem Cells for Diabetes","volume":"11","author":"Memon","year":"2022","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102261_bib170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11154-021-09632-6","article-title":"Transplantation of fat tissues and iPSC-derived energy expenditure adipocytes to counteract obesity-driven metabolic disorders: Current strategies and future perspectives","volume":"23","author":"Dani","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.xcrm.2025.102261_bib171","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1161\/RES.0000000000000291","article-title":"Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association","volume":"125","author":"Gintant","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.xcrm.2025.102261_bib172","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fcell.2020.00178","article-title":"A Brief Review of Current Maturation Methods for Human Induced Pluripotent Stem Cells-Derived Cardiomyocytes","volume":"8","author":"Ahmed","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.xcrm.2025.102261_bib173","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.855763","article-title":"Human Engineered Heart Tissue Models for Disease Modeling and Drug Discovery","volume":"10","author":"Tani","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.xcrm.2025.102261_bib174","doi-asserted-by":"crossref","DOI":"10.1242\/dev.156166","article-title":"Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond","volume":"145","author":"Liu","year":"2018","journal-title":"Development"},{"key":"10.1016\/j.xcrm.2025.102261_bib175","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1038\/s41467-021-25329-5","article-title":"Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease","volume":"12","author":"Lewis-Israeli","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102261_bib176","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/dom.15390","article-title":"The application of organoid models in research into metabolic diseases","volume":"26","author":"Song","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.xcrm.2025.102261_bib177","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41574-022-00733-z","article-title":"Modelling metabolic diseases and drug response using stem cells and organoids","volume":"18","author":"Hu","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.xcrm.2025.102261_bib178","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1016\/j.cell.2021.04.034","article-title":"Cardioids reveal self-organizing principles of human cardiogenesis","volume":"184","author":"Hofbauer","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102261_bib179","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.cell.2018.11.042","article-title":"A Platform for Generation of Chamber-Specific Cardiac Tissues and Disease Modeling","volume":"176","author":"Zhao","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102261_bib180","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41587-023-01680-4","article-title":"Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis","volume":"41","author":"Hendriks","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102261_bib181","doi-asserted-by":"crossref","first-page":"e2301499","DOI":"10.1002\/advs.202301499","article-title":"Scalable Generation of Pre-Vascularized and Functional Human Beige Adipose Organoids","volume":"10","author":"Escudero","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xcrm.2025.102261_bib182","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.yjmcc.2021.04.006","article-title":"Reconstructing the heart using iPSCs: Engineering strategies and applications","volume":"157","author":"Cho","year":"2021","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.xcrm.2025.102261_bib183","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.stemcr.2020.11.013","article-title":"Engineered models of the human heart: Directions and challenges","volume":"16","author":"Stein","year":"2021","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102261_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101951","article-title":"Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue","volume":"41","author":"Rhoden","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.xcrm.2025.102261_bib185","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41551-020-0539-4","article-title":"Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity","volume":"4","author":"Richards","year":"2020","journal-title":"Nat Biomed Eng."},{"key":"10.1016\/j.xcrm.2025.102261_bib186","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.118.037357","article-title":"Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer","volume":"139","author":"Kitani","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.xcrm.2025.102261_bib187","first-page":"100122","article-title":"Modeling immune checkpoint inhibitor associated myocarditis in vitro and its therapeutic implications","volume":"10","author":"Jensen","year":"2024","journal-title":"J. Mol. Cell Cardiol. Plus"},{"key":"10.1016\/j.xcrm.2025.102261_bib191","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94623","article-title":"A BAG3 chaperone complex maintains cardiomyocyte function during proteotoxic stress","volume":"2","author":"Judge","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2025.102261_bib190","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13287-024-03847-5","article-title":"Secretome from iPSC-derived MSCs exerts proangiogenic and immunosuppressive effects to alleviate radiation-induced vascular endothelial cell damage","volume":"15","author":"Gupta","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.xcrm.2025.102261_bib188","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1172\/JCI43122","article-title":"Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells","volume":"120","author":"Rashid","year":"2010","journal-title":"J. Clin. Inves."},{"key":"10.1016\/j.xcrm.2025.102261_bib189","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13287-019-1342-6","article-title":"Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR\/Cas-mediated genetic correction, and productive hepatitis C virus infection","volume":"10","author":"Caron","year":"2019","journal-title":"Stem Cell Res. Ther."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:32:40Z","timestamp":1765888360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125003349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":190,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666379125003349"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102261","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiometabolic disease and cardio-oncology: Insights from iPSC models and tissue engineering","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102261"}}